When a person is placed on a transplant waiting list, time starts moving differently. Life seems to go on, but somewhere in the background there is always a countdown: the constant wait for a call saying that the right organ has been found.
When The Matrix came out in the late 1990s, its most unsettling idea was not the special effects. It was the possibility that consciousness could be placed inside an artificial world — and experience it as real. Back then, it seemed like the kind of science fiction that worked precisely because it felt impossible.
New regulations governing the conduct of clinical trials in the UK come into effect today. This marks the largest package of changes in this sector in over two decades. Thanks to simplified procedures for lower-risk trials and the introduction of fast-track assessment routes, the preparation time for medical tests has already been reduced to 122 days. Furthermore, the publication of trial results becomes a strict legal requirement for the first time.
Imagine a fleet of microscopic machines cruising through your body, vacuuming up dangerous bacteria, and then dropping them off at a designated location on demand. This is no longer a sci-fi movie scenario. Researchers have just unveiled ultra-fast, light-driven nanorobots that could revolutionize medicine and the way we deliver drugs.
The European Commission has officially granted marketing authorization for mCOMBRIAX – the world’s first combined mRNA vaccine against influenza and COVID-19. The approval for the American company Moderna is a breakthrough step in simplifying vaccination campaigns, allowing people over 50 to be protected against two dangerous respiratory viruses with just a single shot.
Instead of helping, they often mislead and legitimize dangerous pseudotherapies. A new, comprehensive study published in BMJ Open proves that nearly half of the medical advice generated by popular AI chatbots is problematic. Doctors are sounding the alarm, warning against a technology that – by giving evasive answers – could deter patients from conventional cancer treatments.
Pharmaceutical giant GSK has presented promising Phase I clinical trial results for its targeted ADC therapy (mocertatug rezetecan). The novel drug, aimed at the B7-H4 antigen, demonstrates exceptionally high efficacy against treatment-resistant ovarian cancer and advanced endometrial cancer, paving the way for large-scale Phase III trials later this year.
Israeli firm ForSight Robotics has announced the successful completion of the first-ever fully robotic cataract surgery on a human patient. The procedure was performed without the need for general anesthesia, a breakthrough that could radically shift global standards and accessibility in ophthalmic care.
Zurich-based Connectome Health has secured $2 million in pre-seed funding to develop its brain health monitoring platform. The Swiss solution analyzes neural signals alongside daily habits, enabling the early detection of subtle cognitive shifts.
Researchers at UC Berkeley have built an “organ-on-a-chip” system that can replicate up to 40 years of human tissue aging in just four days. The technology could speed up the development of anti-aging therapies.